Alto Neuroscience, Inc.
NYSE: ANRO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Amit Etkin
- Employees
- 76
- Headquarters
- Mountain View, United States
- IPO year
- 2024
- Market cap
- $874.2M
- Website
- https://www.altoneuroscience.com
Loading ANRO…
Loading profile data…Frequently asked questions about ANRO
What does Alto Neuroscience, Inc. (ANRO) do?
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is...
Where does ANRO trade?
Alto Neuroscience, Inc. (ANRO) trades on the New York Stock Exchange.
What sector is ANRO in?
Alto Neuroscience, Inc. (ANRO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Alto Neuroscience, Inc.?
Amit Etkin is the chief executive officer of Alto Neuroscience, Inc. (ANRO).
Where is Alto Neuroscience, Inc. headquartered?
Alto Neuroscience, Inc. is headquartered in United States.
Does ANRO pay a dividend?
Alto Neuroscience, Inc. (ANRO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ANRO go public?
Alto Neuroscience, Inc. (ANRO) completed its initial public offering in 2024.